Advertisement

Percutaneous Left Atrial Appendage Closure: Rational, Patient Selection, and Preoperative Evaluation

  • Marco Mennuni
  • Carlo PenzoEmail author
  • Giuseppe Ferrante
  • Giulio Stefanini
  • Bernhard Reimers
Chapter

Abstract

Atrial fibrillation (AF) is the most common arrhythmia, affecting 1–2 % of worldwide population, the incidence is 0.05 % cases per year, and it is expected to more than double by 2050 in the western countries [1]. AF presence increases the risk of embolic stroke by four- to fivefold [2] and results in stroke incidence of 2–5 % per year in untreated patients [3]. Such disabling complication is mainly related to thrombus formation within the left atrial appendage (LAA) [4]. Furthermore, among patients with AF and history of stroke, the rate of new embolic events may increase up to 12 % per year if patients are not on oral anticoagulants and is at 3 % per year in patients who are properly under medical treatment [2].

Keywords

Oral Anticoagulation Left Atrial Appendage CHADS2 Score Left Atrial Appendage Thrombus Left Atrial Appendage Occlusion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Stewart S, Hart CL, Hole DJ, et al. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart. 2001;86(5):516–21.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Peritz DC, Chung EH. Left atrial appendage closure: an emerging option in atrial fibrillation when oral anticoagulants are not tolerated. Cleve Clin J Med. 2015;82(3):167–76.CrossRefPubMedGoogle Scholar
  3. 3.
    Meier B, Blaauw Y, Khattab AA, et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion. Europace. 2014;16(10):1397–416.CrossRefPubMedGoogle Scholar
  4. 4.
    Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864–70.CrossRefPubMedGoogle Scholar
  5. 5.
    Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–100.CrossRefPubMedGoogle Scholar
  6. 6.
    Camm AJ, Lip GY, De Caterina R, et al. Focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719–47.CrossRefPubMedGoogle Scholar
  7. 7.
    Onalan O, Lashevsky I, Hamad A, et al. Nonpharmacologic stroke prevention in atrial fibrillation. Expert Rev Cardiovasc Ther. 2005;3(4):619–33.CrossRefPubMedGoogle Scholar
  8. 8.
    Baker WL, Cios DA, Sander SD, et al. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm. 2009;15(3):244–52.PubMedGoogle Scholar
  9. 9.
    Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62.CrossRefPubMedGoogle Scholar
  10. 10.
    Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.CrossRefPubMedGoogle Scholar
  11. 11.
    Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91.CrossRefPubMedGoogle Scholar
  12. 12.
    Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.CrossRefPubMedGoogle Scholar
  13. 13.
    Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104.CrossRefPubMedGoogle Scholar
  14. 14.
    Al-Saady NM, Obel OA, Camm AJ. Left atrial appendage: structure, function, and role in thromboembolism. Heart. 1999;82(5):547–54.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Kanderian AS, Gillinov AM, Pettersson GB, et al. Success of surgical left atrial appendage closure: assessment by transesophageal echocardiography. J Am Coll Cardiol. 2008;52(11):924–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Block PC, Burstein S, Casale PN, et al. Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) study. JACC Cardiovasc Interv. 2009;2(7):594–600.CrossRefPubMedGoogle Scholar
  17. 17.
    Sievert H, Lesh MD, Trepels T, et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience. Circulation. 2002;105(16):1887–9.CrossRefPubMedGoogle Scholar
  18. 18.
    El-Chami MF, Grow P, Eilen D, et al. Clinical outcomes three years after PLAATO implantation. Catheter Cardiovasc Interv. 2007;69(5):704–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Park JW, Leithauser B, Gerk U, et al. Percutaneous left atrial appendage transcatheter occlusion (PLAATO) for stroke prevention in atrial fibrillation: 2-year outcomes. J Invasive Cardiol. 2009;21(9):446–50.PubMedGoogle Scholar
  20. 20.
    Ussia GP, Mule M, Cammalleri V, et al. Percutaneous closure of left atrial appendage to prevent embolic events in high-risk patients with chronic atrial fibrillation. Catheter Cardiovasc Interv. 2009;74(2):217–22.PubMedGoogle Scholar
  21. 21.
    De Meester P, Thijs V, Van Deyk K, et al. Prevention of stroke by percutaneous left atrial appendage closure: short term follow-up. Int J Cardiol. 2010;142(2):195–6.CrossRefPubMedGoogle Scholar
  22. 22.
    Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009;374(9689):534–42.CrossRefPubMedGoogle Scholar
  23. 23.
    Reddy VY, Sievert H, Halperin J, et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA. 2014;312(19):1988–98.CrossRefPubMedGoogle Scholar
  24. 24.
    Holmes Jr DR, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;64(1):1–12.CrossRefPubMedGoogle Scholar
  25. 25.
    Holmes Jr DR, Doshi SK, Kar S, et al. Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis. J Am Coll Cardiol. 2015;65(24):2614–23.CrossRefPubMedGoogle Scholar
  26. 26.
    Nietlispach F, Gloekler S, Krause R, et al. Amplatzer left atrial appendage occlusion: single center 10-year experience. Catheter Cardiovasc Interv. 2013;82(2):283–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Khattab AA, Meier B. Transcatheter left atrial appendage closure for stroke prevention among atrial fibrillation patients. Expert Rev Cardiovasc Ther. 2012;10(7):819–21.CrossRefPubMedGoogle Scholar
  28. 28.
    Lopez-Minguez JR, Eldoayen-Gragera J, Gonzalez-Fernandez R, et al. Immediate and one-year results in 35 consecutive patients after closure of left atrial appendage with the amplatzer cardiac plug. Rev Esp Cardiol (Engl Ed). 2013;66(2):90–7.CrossRefGoogle Scholar
  29. 29.
    Urena M, Rodes-Cabau J, Freixa X, et al. Percutaneous left atrial appendage closure with the AMPLATZER cardiac plug device in patients with nonvalvular atrial fibrillation and contraindications to anticoagulation therapy. J Am Coll Cardiol. 2013;62(2):96–102.CrossRefPubMedGoogle Scholar
  30. 30.
    Reddy VY, Akehurst RL, Armstrong SO, et al. Time to cost-effectiveness following stroke reduction strategies in AF: warfarin versus NOACs versus LAA closure. J Am Coll Cardiol. 2015;66(24):2728–39.CrossRefPubMedGoogle Scholar
  31. 31.
    Klein AL, Grimm RA, Murray RD, et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med. 2001;344(19):1411–20.CrossRefPubMedGoogle Scholar
  32. 32.
    Hur J, Kim YJ, Nam JE, et al. Thrombus in the left atrial appendage in stroke patients: detection with cardiac CT angiography – a preliminary report. Radiology. 2008;249(1):81–7.CrossRefPubMedGoogle Scholar
  33. 33.
    Shapiro MD, Neilan TG, Jassal DS, et al. Multidetector computed tomography for the detection of left atrial appendage thrombus: a comparative study with transesophageal echocardiography. J Comput Assist Tomogr. 2007;31(6):905–9.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  • Marco Mennuni
    • 1
  • Carlo Penzo
    • 2
    Email author
  • Giuseppe Ferrante
    • 1
  • Giulio Stefanini
    • 1
  • Bernhard Reimers
    • 1
  1. 1.Cardiovascular DepartmentHumanitas Research HospitalMilanItaly
  2. 2.Cardiovascular DepartmentMirano HospitalMiranoItaly

Personalised recommendations